Table 3.
RP of immunotherapy related studies
| Drugs | Study | Published year | study type | No. of cases | Radiation dose(Gy) | RP rate(%) |
|---|---|---|---|---|---|---|
| Durvalumab | Pacific study [83] | 2017 | Clinical Trial | 713 | 54–66 | 33.9 |
| Moore [97] | 2020 | Clinical Trial | 39 | 60 | 54.0 | |
| Inoue [98] | 2020 | retrospective study | 30 | 60–64 |
73.0 > 3Grade: 0 |
|
| Atezolizumab | Lin S H [95] | 2020 | Clinical Trial | 52 | 66 | P1:10.0;P2:16.0 |
| Nivolumab | Peters S [94] | 2021 | Clinical Trial | 79 | 66 | > 3Grade: 11.7 |
| ICI + RT | Botticella A [89] | 2019 | retrospective study | 318 | 50–60 | 16.7 |
| Pembrolizumab | Verma V [127] | 2018 | retrospective study | 60 | 50–60 | > 3Grade: A:25;B:5;C:36 |
| Keynote-001 [90] | 2017 | Clinical Trial | 550 | / |
A:40;B:63 > 3Grade: A:12;B:17 |
|
|
Durm G A [91] (Lun14-179) |
2020 | Clinical Trial | 93 | 59.4–66.6 | > 2Grade: 15.2 | |
| Keynote-799 [92] | 2021 | Clinical Trial | 216 | 60 |
A:17.9;B:7.8 > 3Grade: A:1.8;B:1.0; |
|
| Jabbour S K [93] | 2020 | Clinical Trial | 21 | 60 |
33.0 > 3Grade: 2.0 |
|
| ICI + SBRT | TIAN S [26] | 2019 | Clinical Trial | 117 | SBRT |
33.9 > 3Grade: 10.7 |
RP Radiation pneumonitis, SBRT Stereotactic Body Radiotherapy, RT Radiation Therapy, ICI Immune checkpoint inhibitor